SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chimerix, Inc. Buyout Mar 5, 2025 01:17PM
Chimerix (CMRX) to Resume Trading at 7:30 a.m. Mar 5, 2025 07:05AM
JAZZ (JAZZ) to Acquire Chimerix (CMRX) for $8.55/sh Cash Mar 5, 2025 07:02AM
Chimerix (CMRX) Halted, News Pending Mar 5, 2025 06:58AM
Chimerix (CMRX) Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Feb 18, 2025 07:03AM


Jan 6, 2025 10:35AM TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
Dec 31, 2024 06:33AM H.C. Wainwright Reiterates Buy Rating on Chimerix (CMRX)
Dec 30, 2024 07:02AM Chimerix (CMRX) Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Dec 9, 2024 04:02PM Chimerix (CMRX) to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Nov 11, 2024 07:01AM Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone
Nov 7, 2024 07:04AM Chimerix (CMRX) Misses Q3 EPS by 2c
Aug 14, 2024 11:07AM TD Cowen Reiterates Buy Rating on Chimerix (CMRX)
Aug 13, 2024 07:02AM Chimerix (CMRX) Reports In-Line Q2 EPS